MO · CIK 764180
What Altria Group, Inc. told the SEC could break it.
Altria's heaviest disclosed exposure is distributor concentration: in 2025 one customer was about 23% of consolidated net revenues and a second about 19% — roughly 42% combined — with no other customer above 10%, and it separately leans on a few significant facilities and a small number of key suppliers and distribution-chain providers, so a disruption at either end could materially hurt it. The rest of its register is the regulatory and legal weather of tobacco: its e-vapor and oral-nicotine products depend on FDA marketing orders under the PMTA regime, illicit flavored disposables make up roughly 70% of the e-vapor category, and NJOY ACE is under ITC exclusion and cease-and-desist orders barring U.S. sale. It also flags material litigation, including 17 putative antitrust class actions, four Canadian class actions, and e-vapor patent suits.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- two customers = ~23% and ~19% of consolidated net revenues (~42% combined)high
In 2025, one customer accounted for ~23% and a second ~19% of Altria's consolidated net revenues (~42% combined), substantially all in the smokeable, oral tobacco and e-vapor segments; no other customer exceeded 10% — heavy distributor concentration.
“we had one customer that accounted for approximately 23 %, 22 % and 25 % of our consolidated net revenues, respectively, and one customer that accounted for approximately 19 %, 20 % and 23 % of our consolidated net revenues, respectively.”
SEC filing →As of 2026
Litigation
- tobacco/e-vapor litigation — antitrust class actions, Canada class actions, JUUL/Fuma patent suitsmedium
Altria faces 17 putative class-action antitrust lawsuits and four class actions in Canada not covered by prior settlements, plus e-vapor patent litigation (e.g., Fuma International's suit against Altria, Nu Mark, AGDC, ALCS and NJOY), creating material legal exposure.
“Neither settlement applies to four class action lawsuits pending in Canada or 17 putative class action antitrust lawsuits.”
SEC filing →As of 2026
Regulatory & policy
- FDA marketing-order regime (MGO/MDO/PMTA) for e-vapor & oral nicotine; illicit flavored disposables ~70% of e-vapor; NJOY ITC exclusion ordersmedium
Altria's e-vapor and oral-nicotine products depend on FDA marketing orders (MGOs/MDOs under PMTA); illicit flavored disposable e-vapor products represent ~70% of the e-vapor category, and NJOY ACE is subject to ITC exclusion and cease-and-desist orders prohibiting U.S. importation and sale — constraining its e-vapor growth.
“NJOY ACE is subject to ITC exclusion and cease-and-desist orders prohibiting importation and sale in the United States.”
SEC filing →As of 2026
Supplier concentration
- reliance on a few significant facilities and a small number of key suppliers/distributors/distribution-chain providersmedium
Altria's operating companies rely on a few significant facilities and a small number of key suppliers, distributors and distribution-chain service providers; an extended disruption at a facility or in service by a supplier/distributor could materially adversely affect the business.
“Our operating companies rely on a few significant facilities and a small number of key suppliers, distributors and distribution chain service providers, and an extended disruption at a facility or in service by a supplier, distributor or distribution chain service provider could have a material adverse effect on our busine[ss]”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch